NCT04166435View on ClinicalTrials.gov

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

January 6, 2022

Study Completion Date

June 12, 2023

Conditions
Colorectal Cancer
Interventions
DRUG

Temozolomide + Olaparib

Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.

Trial Locations (1)

06512

Yale New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT04166435 - TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer | Biotech Hunter | Biotech Hunter